- 2.3% of the adult French population suffers from heart failure in France, according to Santé Publique France.
- Between 400,000 and 700,000 people suffer from heart failure without knowing it, according to Health Insurance.
About 80,000 people have a myocardial infarction –also called heart attack– every year in France, according to health insurance. This cardiac event can be defined as the destruction of a part of the heart muscle. Often it leaves sequelae because there is an irreversible loss of heart cells.
Myocardial infarction: 3 proteins to prevent heart failure
Some patients suffer from heart failure after a heart attack. This chronic disease is characterized by the inability of the heart muscle to normally perform its role of pumping blood through the body. Treatments and a healthy lifestyle can prevent worsening and limit the occurrence of episodes of decompensation where patients need to be hospitalized.
According to‘Health insurance, heart attack is the most common cause of heart failure. Researchers have therefore worked to limit the risk of heart failure after a myocardial infarction. Their study has just been published in the journal Science translational medicine.
The researchers discovered three proteins that, administered after a heart attack, could prevent the onset of heart failure. For this, they used a technology called “FunSel”, which managed to identify these three human proteins among a thousand. These are Chrdl1, Fam3c and Fam3b.
Administration of protein after a heart attack
“This is the first time ever that potentially heart-healing factors have been directly identified for their therapeutic potential“, explains Mauro Giacca, one of the authors of the study in a communicated. According to experiments carried out in the laboratory on mice, these three proteins would prevent heart damage after a heart attack and thus prevent the risk of heart failure.
“Any of the three proteins we have identified can be given immediately after a heart attack to minimize heart damage and thereby prevent heart failure, developer Mauro Giacca. There hasn’t been a significant breakthrough in this area for a long time, so we’re very excited about this discovery.“
Currently, the effectiveness of these three proteins has only been demonstrated in mice, but they should soon be tested in humans. “The potential of this therapy is extremely important and could revolutionize treatments for patients at risk of heart failure.concludes Ajay Shah, professor and director of British Heart Foundation Center for Research Excellence at King’s College London. There is no effective preventive treatment for the deterioration of heart tissue after one [infarctus du myocarde]so this is a big step forward in this area.“